The Heterogeneity of Prostate Cancer: Implications for Research

  • Andrew C. von Eschenbach


Cancer does not treat all its victims equally. Some progress rapidly from diagnosis to death; in others the disease advances almost imperceptibly. This variation in malignant expression is certainly apparent from one type of cancer to another. In the case of melanoma and basal cell carcinomas of the skin, for example, even the same tumor type may act differently in two patients. As a model of heterogeneity, prostate cancer is of particular importance because of its variable behavior in patients belonging to various minorities (Young et al. 1984).


Prostate Cancer Basal Cell Carcinoma Osseous Metastasis American Black Malignant Tumor Type 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brawn PN, Ayala AG, von Eschenbach AC, et al: Histologic grading study of prostate adenocarcinoma. Cancer 1982; 49:525–532.PubMedCrossRefGoogle Scholar
  2. Dayal HH, Chiu C: Factors associated with racial differences in survival for prostatic carcinoma. J Clin Res 1982; 35:553–560.Google Scholar
  3. Gleason DF, Mellinger GT, and The Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 3:58–64.Google Scholar
  4. Grayhack JT, Keeler TC, Kozlowski JM: Carcinoma of the prostate: Hormonal therapy. Cancer 1987; 60:589–601.PubMedCrossRefGoogle Scholar
  5. Haenszel W, Kurihara M: Studies of Japanese migrants I. Mortality from cancer and other diseases among Japanese in the United States. JNCI 1960; 40:43–68.Google Scholar
  6. Johnson DE, Swanson DA, von Eschenbach AC. Tumors of the genitourinary tract. In Tanagho EA, McAninch JW, eds, General Urology, 12th Ed. Norwalk: Appleton & Lange, 1988.Google Scholar
  7. Logothetis CJ, Samuels ML, von Eschenbach AC, et al: Doxorubicin, mitomycin-C and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate with a note on the staging metastatic prostate cancer. J Clin Onocol 1983; 1:368–379.Google Scholar
  8. Mettlin C, Natarajan N: Epidemiologic observation from the American College of Surgeons survey on prostate cancer. Prostate 1983; 4:323–331.PubMedCrossRefGoogle Scholar
  9. Rose DP: The biochemical epidemiology of prostatic carcinoma. In: Dietary Fat and Cancer, New York: Alan R Liss, 1986, pp 43–68.Google Scholar
  10. Thind, IS, Najem R, Paradise J, et al: Cancer among blacks in Newark, New Jersey 1970–1976. Cancer 1982; 50:180–186.PubMedCrossRefGoogle Scholar
  11. Young JL Jr, Ries GL, Pollack ES: Cancer patient survival among ethnic groups in the United States. JNCI 1984; 73:341–352.PubMedGoogle Scholar
  12. Whitmore WF Jr: The natural history of prostate cancer. Cancer 1973; 31:1104–1112.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • Andrew C. von Eschenbach

There are no affiliations available

Personalised recommendations